News

On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28, and the S&P 500 closed at 1,949.44, up 0.46%. The gains were broad based...

US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from its DCVex lentiviral vector platform to treat patients with locally advanced, relapsed, or metastatic breast cancer, melanoma, non-small cell...

US-based biotechnology firm Edge Therapeutics has started enrolling patients in the second group of a multicenter, randomised, controlled, open-label, Phase I/II NEWTON trial of its lead product candidate, EG-1962, for the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH)....

US-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to treat a number of autoimmune diseases. ...

The future of medicine, we're often told, will be personalized. We'll have gene therapies, wearables to monitor our vital signs—maybe even new kinds of vital signs—and robot doctors to diagnose our illnesses. But the real promise...

UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes in adult patients uncontrolled on oral antidiabetic drugs. ...

US-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown in patients with type 2 diabetes taking metformin. Accumed Research Associates is conducting the 24-patient five-week,...